HPC3
MCID: PRS134
MIFTS: 20

Prostate Cancer, Hereditary, 3 (HPC3)

Categories: Cancer diseases, Genetic diseases, Rare diseases, Reproductive diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Prostate Cancer, Hereditary, 3

MalaCards integrated aliases for Prostate Cancer, Hereditary, 3:

Name: Prostate Cancer, Hereditary, 3 57 12 71
Prostate Cancer, Susceptibility to, 3 57
Prostate Cancer 3 57
Hpc3 57

Classifications:



External Ids:

OMIM® 57 608656
MedGen 40 C1837595
UMLS 71 C1837595

Summaries for Prostate Cancer, Hereditary, 3

MalaCards based summary: Prostate Cancer, Hereditary, 3, also known as prostate cancer, susceptibility to, 3, is related to prostate cancer and prostate cancer, hereditary, 8. An important gene associated with Prostate Cancer, Hereditary, 3 is HPC3 (Prostate Cancer, Hereditary, 3). Affiliated tissues include prostate, bone and testis.

More information from OMIM: 608656

Related Diseases for Prostate Cancer, Hereditary, 3

Graphical network of the top 20 diseases related to Prostate Cancer, Hereditary, 3:



Diseases related to Prostate Cancer, Hereditary, 3

Symptoms & Phenotypes for Prostate Cancer, Hereditary, 3

Clinical features from OMIM®:

608656 (Updated 08-Dec-2022)

Drugs & Therapeutics for Prostate Cancer, Hereditary, 3

Search Clinical Trials, NIH Clinical Center for Prostate Cancer, Hereditary, 3

Genetic Tests for Prostate Cancer, Hereditary, 3

Anatomical Context for Prostate Cancer, Hereditary, 3

Organs/tissues related to Prostate Cancer, Hereditary, 3:

MalaCards : Prostate, Bone, Testis, Endothelial

Publications for Prostate Cancer, Hereditary, 3

Articles related to Prostate Cancer, Hereditary, 3:

(show top 50) (show all 85)
# Title Authors PMID Year
1
Evidence for a prostate cancer linkage to chromosome 20 in 159 hereditary prostate cancer families. 57
11409871 2001
2
Analysis of the prostate cancer-susceptibility locus HPC20 in 172 families affected by prostate cancer. 57
11179028 2001
3
Evidence for a prostate cancer-susceptibility locus on chromosome 20. 57
10820130 2000
4
Isoleucine with secondary sulfonamide functionality as anticancer, antibacterial and antifungal agents. 62
33704017 2022
5
Multiple cells of origin in common with various types of mouse N-Myc acute leukemia. 62
35512442 2022
6
Phonon-mediated superconductivity in two-dimensional hydrogenated phosphorus carbide: HPC3. 62
35388845 2022
7
Identifying and Addressing Health Disparities among African American Men with Prostate Cancer: a Systematic Literature Review. 62
33474714 2022
8
Assessment of oncological and functional outcomes of retropubic radical prostatectomy: An academic center experience. 62
34565670 2021
9
Dietary Melatonin and Omega-3 Fatty Acids Induce Human Cancer Xenograft Regression In Vivo in Rats by Suppressing Linoleic Acid Uptake and Metabolism. 62
34187631 2021
10
Magnetic resonance imaging-guided transurethral ultrasound ablation in patients with localised prostate cancer: 3-year outcomes of a prospective Phase I study. 62
33037765 2021
11
Clinical effects of rectal retractor application in prostate cancer radiotherapy. 62
34277506 2021
12
Pelvic radiation therapy as a potential risk factor for ischemic colitis complicating abdominal aortic reconstruction. 62
32715182 2020
13
On-chip RT-LAMP and colorimetric detection of the prostate cancer 3 biomarker with an integrated thermal and imaging box. 62
31816706 2020
14
A DSTYK mutation activates ERK1/2 signaling to promote intraspinal dissemination in a case of solitary fibrous tumor/hemangiopericytoma. 62
31201369 2019
15
Management of advanced prostate cancer in a middle-income country: real-world consideration of the Advanced Prostate Cancer Consensus Conference 2017. 62
31077523 2019
16
Mouse acute leukemia develops independent of self-renewal and differentiation potentials in hematopoietic stem and progenitor cells. 62
30733302 2019
17
Correlation of mRNA-PCA3 urine levels with the new grading system in prostate cancer. 62
30583827 2019
18
Design, Synthesis and Biological Evaluation of 4-Aryl-5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one Derivatives as a PI3Kα Inhibitor. 62
31155575 2019
19
Palladium nanoparticle-decorated 2-D graphene oxide for effective photodynamic and photothermal therapy of prostate solid tumors. 62
29843117 2018
20
Long-Term Antitumor Activity and Safety of Enzalutamide Monotherapy in Hormone Naïve Prostate Cancer: 3-Year Open Label Followup Results. 62
28867562 2018
21
Diffusion Kurtosis Imaging Helps to Predict Upgrading in Biopsy-Proven Prostate Cancer With a Gleason Score of 6. 62
28834443 2017
22
Extended Follow-up of Patients Treated With Bendamustine for Lymphoid Malignancies. 62
28797620 2017
23
Study on the influence of metformin on castration-resistant prostate cancer PC-3 cell line biological behavior by its inhibition on PLCε gene-mediated Notch1/Hes and androgen receptor signaling pathway. 62
28485785 2017
24
Evaluation of a short RNA within Prostate Cancer Gene 3 in the predictive role for future cancer using non-malignant prostate biopsies. 62
28380027 2017
25
Prostate-Specific Membrane Antigen Uptake in Small Cleaved B-Cell Follicular Non-Hodgkin Lymphoma. 62
27749416 2016
26
Prostate-Specific Membrane Antigen (PSMA) Avid Pancreatic Neuroendocrine Tumor. 62
27454602 2016
27
Clinical Use of PCA3 and TMPRSS2:ERG Urinary Biomarkers in African-American Men Undergoing Prostate Biopsy. 62
27140073 2016
28
Choosing Wisely® in Preventive Medicine: The American College of Preventive Medicine's Top 5 List of Recommendations. 62
27155735 2016
29
Bilateral Choroidal Metastases from Prostate Cancer revealed in a patient under Abiraterone - Fourteen years after diagnosis. 62
27250892 2016
30
Inhibition of Survivin Is Associated with Zoledronic Acid-induced Apoptosis of Prostate Cancer Cells. 62
26976978 2016
31
[Prostate cancer incidence and mortality trends in France from 1980 to 2011]. 62
26043950 2015
32
Photobleaching of fluorescein as a probe for oxidative stress in single cells. 62
25218588 2014
33
Androgen receptor and gene network: Micromechanics reassemble the signaling machinery of TMPRSS2-ERG positive prostate cancer cells. 62
24739220 2014
34
Molecular effects of bioactive fraction of Curcuma mangga (DLBS4847) as a downregulator of 5α-reductase activity pathways in prostatic epithelial cells. 62
24944518 2014
35
Detection and quantification of enzymatically active prostate-specific antigen in vivo. 62
23933968 2013
36
A comparison of US and Australian men's values and preferences for PSA screening. 62
24093428 2013
37
[Safety and effectiveness of testicular prosthesis implantation for testis loss: clinical observation of 18 cases]. 62
22574373 2012
38
Surrogate endpoints for prostate cancer-specific mortality after radiotherapy and androgen suppression therapy in men with localised or locally advanced prostate cancer: an analysis of two randomised trials. 62
22112793 2012
39
Investigation on tumor hypoxia in resectable primary prostate cancer as demonstrated by 18F-FAZA PET/CT utilizing multimodality fusion techniques. 62
21833840 2011
40
Identification of an exon 4-deletion variant of epidermal growth factor receptor with increased metastasis-promoting capacity. 62
21532887 2011
41
Urinary prostate cancer 3 test: toward the age of reason? 62
19586654 2010
42
Robotic-assisted minimally invasive surgery for gynecologic and urologic oncology: an evidence-based analysis. 62
23074405 2010
43
The bioactive compounds alpha-chaconine and gallic acid in potato extracts decrease survival and induce apoptosis in LNCaP and PC3 prostate cancer cells. 62
20574921 2010
44
Salvage brachytherapy for local recurrences of prostate cancer treated previously with radiotherapy. 62
28050174 2009
45
[Molecular markers associated with prostate cancer: 3-nitrotyrosine and genetic and proteic expression of Mn-superoxide dismutasa (Mn-SOD)]. 62
19955594 2009
46
[Prognosis and predictive factors in prostate cancer]. 62
19357018 2009
47
Granulocyte macrophage colony-stimulating factor may modulate the post-transcription pathway of interleukin-6 expression in prostate carcinoma cells. 62
18303206 2008
48
Association between polymorphisms in HSD3B1 and UGT2B17 and prostate cancer risk. 62
17826523 2007
49
Reduced tumor growth in vivo and increased c-Abl activity in PC3 prostate cancer cells overexpressing the Shb adapter protein. 62
17697368 2007
50
Effects of flutamide on [methyl-(3)h]-choline uptake in human prostate cancer-3 cells: a pilot study. 62
24683213 2007

Variations for Prostate Cancer, Hereditary, 3

Expression for Prostate Cancer, Hereditary, 3

Search GEO for disease gene expression data for Prostate Cancer, Hereditary, 3.

Pathways for Prostate Cancer, Hereditary, 3

GO Terms for Prostate Cancer, Hereditary, 3

Sources for Prostate Cancer, Hereditary, 3

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....